Fibrinolytic capacity increases with age in healthy humans, while endothelium-dependent vasodilation is unaffected

Thorarinn Gudnason; Thórdís Hrafnkelsdóttir; Ulrika Wall; Karl Swedberg; Sverker Jern

doi:10.1055/s-0037-1613455

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2003; 89(02): 374-382
DOI: 10.1055/s-0037-1613455

Vascular Development and Vessel Remodelling

Schattauer GmbH

Fibrinolytic capacity increases with age in healthy humans, while endothelium-dependent vasodilation is unaffected

Thorarinn Gudnason

¹Clinical Experimental Research Laboratory, Department of Medicine, Sahlgrenska University Hospital/östra and the Cardiovascular Institute, Göteborg University, Göteborg, Sweden

,

Thórdís Hrafnkelsdóttir

¹Clinical Experimental Research Laboratory, Department of Medicine, Sahlgrenska University Hospital/östra and the Cardiovascular Institute, Göteborg University, Göteborg, Sweden

,

Ulrika Wall

¹Clinical Experimental Research Laboratory, Department of Medicine, Sahlgrenska University Hospital/östra and the Cardiovascular Institute, Göteborg University, Göteborg, Sweden

,

Karl Swedberg

¹Clinical Experimental Research Laboratory, Department of Medicine, Sahlgrenska University Hospital/östra and the Cardiovascular Institute, Göteborg University, Göteborg, Sweden

,

Sverker Jern

¹Clinical Experimental Research Laboratory, Department of Medicine, Sahlgrenska University Hospital/östra and the Cardiovascular Institute, Göteborg University, Göteborg, Sweden

› Institutsangaben

Abstract

Summary

The capacity for stimulated endothelial release of tissue-type plasminogen activator (tPA) and endothelium-dependent vasodilation is diminished in patients with cardiovascular risk factors. We examined the effect of age on desmopressin-stimulated tPA release and endothelium-dependent vasodilation, using the perfused-forearm model. Thirty-two healthy subjects were divided into quartiles by age (mean age 24, 36, 54, and 72 years, respectively). Baseline fibrinolytic parameters, baseline forearm blood flow (FBF), and increase in stimulated FBF were all similar across age. By contrast, the capacity for desmopressin-stimulated release of tPA increased linearly by age. For tPA antigen, the total amount released (area-under-the-curve) was 1015, 1282, 2139, and 2845 ng/L tissue (p = 0.011) and the peak release rates were 62, 80, 113, and 163 ng/min/L tissue (p = 0.008) in the age-quartiles, respectively. A similar significant age-related response was observed for tPA activity. We conclude that in healthy individuals there is an up-regulation of the fibrinolytic response by age.

Keywords

Fibrinolysis - tissue-type plasminogen activator - endothelium - human - ageing

Volltext

Referenzen

References
1 Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313 (25) 1557-63.
2 Hoffmeister HM, Jur M, Ruf-Lehmann M, Helber U, Heller W, Seipel L. Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction. J Am Coll Cardiol 1998; 31 (03) 547-51.
3 Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F. et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98 (21) 2241-7.
4 Wiman B, Andersson T, Hallqvist J, Reuter-wall C, Ahlbom A, deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Wille-brand factor are significant risk markers for recurrent myocardial infarction in the Stock-holm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20 (08) 2019-23.
5 Newby DE, Witherow FN, Wright RA, Bloomfield P, Ludlam CA, Boon NA. et al. Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo. Heart 2002; 87 (01) 48-53.
6 Walmsley D, Hampton KK, Grant PJ.. Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes. Diabet Med 1991; 8 (10) 954-9.
7 Allen RA, Kluft C, Brommer EJ. Acute effect of smoking on fibrinolysis: increase in the activity level of circulating extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14 (05) 354-61.
8 Jern S, Wall U, Bergbrant A, Selin-Sjogren L, Jern C.. Endothelium-dependent vasodilation and tissue-type plasminogen activator release in borderline hypertension. Arterioscler Thromb Vasc Biol 1997; 17 (12) 3376-83.
9 Wall U, Jern C, Bergbrant A, Jern S. Enhanced levels of tissue-type plasminogen activator in borderline hypertension. Hypertension 1995; 26 (05) 796-800.
10 Hrafnkelsdottir T, Wall U, Jern C, Jern S. Impaired capacity for endogenous fibrinolysis in essential hypertension [letter]. Lancet 1998; 352 9140 1597-8.
11 Allen RA, Kluft C, Brommer EJ. Effect of chronic smoking on fibrinolysis. Arteriosclerosis 1985; 5 (05) 443-50.
12 Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA. et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999; 99 (11) 1411-5.
13 Avellone G, Di Garbo V, Cordova R, Rotolo G, Abruzzese G, Raneli G. et al. Blood coagulation and fibrinolysis in obese NIDDM patients. Diabetes Res 1994; 25 (02) 85-92.
14 Vogel RA. Coronary risk factors, endothelial function, and atherosclerosis: a review. Clin Cardiol 1997; 20 (05) 426-32.
15 De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130 (05) 963-74.
16 Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol 1994; 23 (07) 1610-6.
17 Vanhoutte PM, Boulanger CM. Endothelium-dependent responses in hypertension. Hypertens Res 1995; 18 (02) 87-98.
18 Heitzer T, Yla-Herttuala S, Luoma J, Kurtz S, Munzel T, Just H. et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hyper-cholesterolemia. Role of oxidized LDL. Circulation 1996; 93 (07) 1346-53.
19 Landmesser U, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost 2000; 26 (05) 529-37.
20 Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J. et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88 5 PT 1 2149-55.
21 Vanhoutte PM. Ageing and endothelial dysfunction. Eur Heart J 2002; 4 SUPPL A A8-17.
22 Gerhard M, Roddy MA, Creager SJ, Creager MA. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996; 27 (04) 849-53.
23 Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB. et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91 (07) 1981-7.
24 Taddei S, Virdis A, Mattei P, Ghiadoni L, Fasolo CB, Sudano I. et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997; 29 (03) 736-43.
25 Taddei S, Galetta F, Virdis A, Ghiadoni L, Salvetti G, Franzoni F. et al. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. Circulation 2000; 101 (25) 2896-901.
26 Chauhan A, More RS, Mullins PA, Taylor G, Petch MC, Schofield PM.. Aging-associated endothelial dysfunction in humans is reversed by L-arginine. J Am Coll Cardiol 1996; 28 (07) 1796-804.
27 Egashira K, Inou T, Hirooka Y, Kai H, Sugimachi M, Suzuki S. et al. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation 1993; 88 (01) 77-81.
28 Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92 (02) 652-62.
29 Meyers DG, Haire WD, Rasmussen JK, Boyd EJ. Tissue plasminogen activator release and plasminogen activator inhibitor levels in coronary artery disease. Angiology 1991; 42 (07) 561-7.
30 Stegnar M, Keber D, Pentek M, Vene N, Kluft C. Age and sex differences in resting and postocclusion values of tissue plasminogen activator in a healthy population. Fibrinolysis 1988; Supp 2 (02) 121-2.
31 Buczko W, Iacoviello L, De Curtis A, Amore C, Donati MB. Aging and tissue plasminogen activator release. Thromb Haemost 1991; 66 (06) 745
32 Emeis JJ, Brouwer A, Barelds RJ, Horan MA, Durham SK, Kooistra T.. On the fibrinolytic system in aged rats, and its reactivity to endo-toxin and cytokines. Thromb Haemost 1992; 67 (06) 697-701.
33 Iacoviello L, D’Adamo MC, De Curtis A, Buczko W, Donati MB. Enhanced vascular plasminogen activator (t-PA) release by epinephrine in aged rats. Thromb Haemost 1995; 73 (05) 841-4.
34 Emeis JJ, van den Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W, Westmuckett A, Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997; 139 (01) 245-56.
35 Emeis JJ. Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products. Ann NY Acad Sci 1992; 667: 249-58.
36 Giles AR, Nesheim ME, Herring SW, Hoogendoorn H, Stump DC, Heldebrant CM. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost 1990; 63 (03) 476-81.
37 Hrafnkelsdottir T, Erlinge D, Jern S. Extracellular nucleotides ATP and UTP induce a marked acute release of tissue-type plasminogen activator in vivo in man. Thromb Haemost 2001; 85 (05) 875-81.
38 Jern C, Selin L, Jern S. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress. Thromb Haemost 1994; 72 (02) 285-91.
39 Jern S, Selin L, Bergbrant A, Jern C. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm. Thromb Haemost 1994; 72 (04) 588-94.
40 Jern C, Selin L, Tengborn L, Jern S.. Sympathoadrenal activation and muscarinic receptor stimulation induce acute release of tissue-type plasminogen activator but not von Willebrand factor across the human forearm. Thromb Haemost 1997; 78 (02) 887-91.
41 Jern C, Ladenvall P, Wall U, Jern S. Gene polymorphism of t-PA is associated with forearm vascular release rate of t-PA. Arterioscler Thromb Vasc Biol 1999; 19 (02) 454-9.
42 Manhem K, Dotevall A, Wilhelmsen L, Jern S. Preserved tissue-type plasminogen activator release and endothelium-dependent vasodilation in postmenopausal women with NIDDM. J Diabetes Complications 2000; 14 (03) 127-34.
43 Wall U, Jern C, Jern S. High capacity for tissue-type plasminogen activator release from vascular endothelium in vivo. J Hypertens 1997; 15 12 PT 2 1641-7.
44 Wall U, Jern S, Tengborn L, Jern C. Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm. Blood 1998; 91 (02) 529-37.
45 Aldasoro M, Medina P, Vila JM, Otero E, Martinez-Leon JB, Lluch S. Endothelium-dependent relaxation of human saphenous veins in response to vasopressin and desmopressin. J Vasc Surg 1997; 25 (04) 696-703.
46 Hasunuma K, Yamada K, Tamura Y, Yoshida S. Cardiovascular and renin responses to desmopressin in humans: role of prostacyclin and beta-adrenergic systems. Am J Physiol 1991; 260 4 PT 2 H1031-6.
47 Rector TS, Bank AJ, Tschumperlin LK, Mullen KA, Lin KA, Kubo SH.. Abnormal desmopressin-induced forearm vasodilatation in patients with heart failure: dependence on nitric oxide synthase activity. Clin Pharmacol Ther 1996; 60 (06) 667-74.
48 Toda M, Ayajiki K, Okamura T, Azuma I, Toda N. Desmopressin-induced dog ciliary artery relaxation. Eur J Pharmacol 1998; 344 2-3 197-201.
49 Medina P, Segarra G, Vila JM, Chuan P, Domenech C, Lluch S. V2-receptor-mediated relaxation of human renal arteries in response to desmopressin. Am J Hypertens 1999; 12 2 PT 1 188-93.
50 Mechaly I, Laurent F, Portet K, Serrano J, Cros G.. Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol 1999; 383 (03) 287-90.
51 Yamada K, Nakayama M, Nakano H, Mimura N, Yoshida S. Endothelium-dependent vaso-relaxation evoked by desmopressin and involvement of nitric oxide in rat aorta. Am J Physiol 1993; 264 2 PT 1 E203-7.
52 Flordal PA, Svensson J, Ljungström KG. Effects of desmopressin and dextran on coagulation and fibrinolysis in healthy volunteers. Thromb Res 1991; 62 (05) 355-64.
53 DeSouza CA, Shapiro LF, Clevenger CM, Dinenno FA, Monahan KD, Tanaka H. et al. Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation 2000; 102 (12) 1351-7.
54 DeSouza CA, Clevenger CM, Greiner JJ, Smith DT, Hoetzer GL, Shapiro LF. et al. Evidence for agonist-specific endothelial vasodilator dysfunction with ageing in healthy humans. J Physiol (Lond) 2002; 542 PT 1 255-62.
55 Imaizumi T, Takeshita A, Suzuki S, Yoshida M, Ando S, Nakamura M. Age-independent forearm vasodilatation by acetylcholine and adenosine 5’-triphosphate in humans. Clin Sci (Lond) 1990; 78 (01) 89-93.